Replies to post #41535 on Cytodyn Inc (CYDY)

[trding]

Our management team keeps improving in addition to the world class CMO.

Did anyone read this new guys bio? An attorney with a Ph.D. in Virology, background in intellectual property, has research in metastasis, just crazy smart. Brilliant addition. Starting with the RP addition last year, we have very smart people are jumping onboard, not including the top clinical sites hosting the TNBC trial: Pacific Hematology Oncology, Northwestern University Medical School, Methodist Houston, Vanderbilt University, Sidney Kimmel Cancer Center.

Brendan Rae, Ph.D., J.D.

Dr. Rae is an accomplished licensing and business development executive with a proven track record of deal-making. Dr. Rae comes to CytoDyn from Serina Therapeutics where he was Chief Business Officer, responsible for partnering, out licensing and overall company strategy. Previously, Dr. Rae was the Executive Director of NPS Pharmaceuticals and Head of GI and Endocrinology Business Development until the acquisition by Shire Pharmaceuticals for $5.2 billion in 2015. Prior to NPS, Dr. Rae held the role of Chief Business Officer at Arrowhead Research and Vivaldi Biosciences, as well as senior leadership roles at VIA Pharmaceuticals, Purdue Pharma and Hoffman-La Roche. Prior to entering the biopharmaceutical industry, Dr. Rae was an attorney specializing in biopharmaceutical intellectual property law and, earlier in his career was a research scientist focusing on metastasis and the molecular basis of cellular transformation. Dr. Rae holds a Juris Doctor degree from Seton Hall Law School and a Ph.D. in Virology from Glasgow University (Scotland) and completed a Postdoctoral Fellowship at the Roche Institute of Molecular Biology.